Navigation Links
Lazarus Effect Closes $5 Million Financing
Date:7/31/2014

CAMPBELL, Calif., July 31, 2014 /PRNewswire/ -- Lazarus Effect, a medical device company focused on the development of novel interventional devices to facilitate removal of blood clots, announced the closing of a $5 million financing. Proceeds from the financing will support EU commercialization of several approved Lazarus Effect devices, as well as regulatory filings for the Lazarus ReCover™ and Lazarus Cover™ in the United States.

"This financing reflects investor confidence in the value of our novel, platform technology as well as our recent IP and regulatory progress," said Martin Dieck, chairman and CEO, Lazarus Effect. "Our expert team has a track record of bringing high-value neurointerventional products to market, and we are grateful to our investors for helping us replicate this success with Lazarus Effect."

Lazarus Effect is developing a complete portfolio of vascular-device products to facilitate removal of blood clots based on a patented, wire-frame technology platform. The company currently has five issued US patents and numerous pending US and worldwide patent applications. The Lazarus Funnel™ Guide Catheter and Lazarus ReCover devices have CE Mark for use in Europe, and the Funnel is cleared for use in the United States. The Lazarus Cover is pending CE Mark. Neither the ReCover nor the Cover are approved for sale in the United States.

New findings from a study evaluating the ability of the Lazarus Cover to prevent emboli during clot retrieval versus the current standard were presented today at the Society of Neurointerventional Surgery (SNIS) 11th Annual Meeting in Colorado Springs, CO.  Alexander Khalessi, MD, MS, director of Endovascular Neurosurgery and surgical director of Neurocritical Care at the University of California, San Diego, shared data from simulated thrombectomy procedures performed in an anatomical model which demonstrated that the Lazarus Cover can protect captured embolic material during withdrawal, potentially reducing the risk of embolization.

Forward-looking Statements

Statements contained in this press release about Lazarus Effect, Inc. that are not purely historical, and all other statements that are not purely historical, may be deemed to be forward-looking statements for purposes of the safe harbor provisions under The Private Securities Litigation Reform Act of 1995. Without limiting the foregoing, the words "believes," "anticipates" and "expects" and similar expressions, are intended to identify forward-looking statements. These forward-looking statements involve known and unknown risks and uncertainties that may cause the Company's actual results, levels of activity, performance or achievements to be materially different from those expressed or implied by these forward-looking statements. Important factors that may cause or contribute to such differences include changes in market or financial conditions, and other changes beyond the control of the Company. The Company specifically disclaims any obligation to update these forward-looking statements.


'/>"/>
SOURCE Lazarus Effect
Copyright©2014 PR Newswire.
All rights reserved

Related medicine technology :

1. Lazarus Effect Receives Notice of Allowance for New US Patent Covering Core Protection Technology
2. Over Half of Audited Multiple Sclerosis Patients Currently Treated with Biogen Idecs Tecfidera Have Experienced Minor Side Effects Although Impact on Use Appears Muted
3. New Data Shows Combination Therapy is More Effective than Monotherapy in Removing Beta-Amyloid Plaques from the Brains of Mice
4. Clinical Trial Demonstrates That EarlySense May Be An Effective Indicator for Respiratory Pattern Recognition
5. New England Journal of Medicine Study Finds Upper-Airway Electronic Stimulation Effective for Obstructive Sleep Apnea
6. ObamaCare: Health Care Reform and its Effect on Sleep Apnea
7. Improving the Quality and Effectiveness of Marketing Services Groups in an Environment Characterized by Globalization and Shrinking Resources
8. New England Journal of Medicine releases study showing GSKs FluLaval Quadrivalent vaccine effective in preventing seasonal flu in children
9. Ibrutinib Data Published in The Lancet Oncology Suggest a Positive Effect in Previously Untreated Chronic Lymphocytic Leukemia Patients Over Age 65
10. Highland Instruments, Inc., Announces Presentation of "Effects of Electrosonic Stimulation on the Perception of Chronic Pain Due to Osteoarthritis of the Knee."
11. Frost & Sullivan Applauds Definiens Strong Technology Portfolio for the Effective Data Analysis of Histology Images
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:2/11/2016)... -- - Cardiac Marker Diagnostic Testing ... Cancer Therapy. - European Point of Care Diagnostic ... - Key Diagnostic Testing Markets. - Molecular Diagnostics ... Testing. - Molecular Diagnostics in Infectious Disease Testing. ... Products World Markets. - Point of Care Diagnostic ...
(Date:2/11/2016)... Feb. 11, 2016 Stem cells are primitive ... by self-renewal and the capacity to differentiate into mature ... discovery, as the first mouse embryonic stem cells were ... until 1995 that the first culturing of embryonic stem ... were not produced until 2006 As a result of ...
(Date:2/11/2016)... 11, 2016 Laboratory glassware and ... laboratories. These may range from microscope slides to large ... made from borosilicate glass because of its low weight ... other hand, started gaining popularity over the past decade ... replace glass with plastic in several applications due to ...
Breaking Medicine Technology:
(Date:2/13/2016)... (PRWEB) , ... February 13, 2016 , ... ... School of Nursing with an in-kind gift of a VeinViewer® Vision vein ... as they learn how to start an IV and draw blood, combining technology ...
(Date:2/13/2016)... ... February 13, 2016 , ... DDi ... Management Solution Providers list for its expertise in eClinical Solutions. DDi has built ... serve the technology needs of global clients. DDi provides smarter technology for Clinical ...
(Date:2/12/2016)... ... February 12, 2016 , ... The law firm of Morrow, Morrow, Ryan & ... purpose of these scholarships is to encourage applicants to pursue a degree in their ... these two parishes. , “We have available jobs in St. Landry and Evangeline ...
(Date:2/12/2016)... ... February 12, 2016 , ... CDRH Enforcement Trends: , Back to the Future , ... , As Winston Churchill said, “Those who don’t learn from history are doomed to ... expect when they come knocking this year. But that takes time. , Take a ...
(Date:2/12/2016)... , ... February 12, 2016 , ... As a former ... schedule, a demanding job, and no time to decompress, Rabinowitz found herself drawn to ... to meditation for its impact on her life, implementing a 20-minute-per-day meditation practice with ...
Breaking Medicine News(10 mins):